FDA grants rolling submission to Luveniq for lupus nephritis.- Aurinia Pharmaceuticals
Aurinia Pharmaceuticals announced that the Company has initiated a Rolling Submission of its New Drug Application to the FDA for Luveniq (voclosporin), a next-generation calcineurin inhibitor for the… read more.

